These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20069293)

  • 1. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
    Jentzen W; Hobbs RF; Stahl A; Knust J; Sgouros G; Bockisch A
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):884-95. PubMed ID: 20069293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.
    Jentzen W; Balschuweit D; Schmitz J; Freudenberg L; Eising E; Hilbel T; Bockisch A; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2298-306. PubMed ID: 20625723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
    Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
    Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.
    Jentzen W; Schneider E; Freudenberg L; Eising EG; Görges R; Müller SP; Brandau W; Bockisch A
    Nucl Med Commun; 2006 Aug; 27(8):669-76. PubMed ID: 16829767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.
    Hobbs RF; Jentzen W; Bockisch A; Sgouros G
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):79-91. PubMed ID: 23474639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrepant salivary gland response after radioiodine and MIBG therapies.
    Jentzen W; Richter M; Poeppel TD; Schmitz J; Brandau W; Bockisch A; Binse I
    Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):331-339. PubMed ID: 25566809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
    Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
    Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy (124)I PET/CT imaging.
    Jentzen W; Richter M; Nagarajah J; Poeppel TD; Brandau W; Dawes C; Bockisch A; Binse I
    EJNMMI Phys; 2014 Dec; 1(1):100. PubMed ID: 26501458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems.
    Jentzen W; Weise R; Kupferschläger J; Freudenberg L; Brandau W; Bares R; Burchert W; Bockisch A
    Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):611-23. PubMed ID: 17929014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
    Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
    J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prompt gamma coincidence correction on absorbed dose estimation in differentiated thyroid cancer using 124I PET/CT imaging.
    Wierts R; Conti M; Claessen AGG; Herrmann K; Kemerink GJ; Binse I; Wildberger JE; Mottaghy FM; Backes WH; Jentzen W
    Nucl Med Commun; 2018 Dec; 39(12):1156-1164. PubMed ID: 30204643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
    Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
    Med Phys; 2016 Oct; 43(10):5279. PubMed ID: 27782699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative performance evaluation of
    Wierts R; Jentzen W; Quick HH; Wisselink HJ; Pooters INA; Wildberger JE; Herrmann K; Kemerink GJ; Backes WH; Mottaghy FM
    Phys Med Biol; 2017 Dec; 63(1):015014. PubMed ID: 29116052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
    Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
    J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT: the significance of changes in volume and attenuation of the glands.
    Nabaa B; Takahashi K; Sasaki T; Okizaki A; Aburano T
    AJNR Am J Neuroradiol; 2012 Nov; 33(10):1964-70. PubMed ID: 22555571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial.
    Liu B; Kuang A; Huang R; Zhao Z; Zeng Y; Wang J; Tian R
    J Nucl Med; 2010 Apr; 51(4):618-23. PubMed ID: 20237029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck.
    Nagarajah J; Jentzen W; Hartung V; Rosenbaum-Krumme S; Mikat C; Heusner TA; Antoch G; Bockisch A; Stahl A
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1862-8. PubMed ID: 21739331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilocarpine effect on dose rate of salivary gland in differentiated thyroid carcinoma patients treated with radioiodine.
    Haghighatafshar M; Ghaedian M; Etemadi Z; Entezarmahdi SM; Ghaedian T
    Nucl Med Commun; 2018 May; 39(5):430-434. PubMed ID: 29517578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
    Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
    Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
    [No Abstract]   [Full Text] [Related]  

  • 20. Salivary gland function in thyroid cancer patients with radioiodine administration history.
    Krcalova E; Horacek J; Gabalec F; Zak P; Dolezal J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Sep; 164(3):277-283. PubMed ID: 31223135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.